Program

Research lines

The full laboratory program. 10 lines, 60 subtopics. Each line builds on the previous one. Active lines have public reports.

L1Completed

Gut-hormone axis (estrobolome)

Connects food directly with hormones: gut bacteria that metabolize estrogens and progestogens, dysbiosis as an accelerator of menopause, and the unique role of the Mesoamerican diet.

6/6 subtopics
L2Completed

HPA-HPO axis: how stress hijacks reproductive hormones

The largest hormonal disruptor for Latin American women. Cortisol, CRH, competition with progesterone, and digital biomarkers of chronic stress.

6/6 subtopics
L3In progress

Thyroid axis and reproductive function

High prevalence in Latin America. TSH as a global cycle modulator, subclinical hypothyroidism and the luteal phase, and thyroid autoimmunity.

4/6 subtopics
L4Coming soon

Hormonal chronobiology

Meal timing and sleep affect hormones. CLOCK/BMAL1 genes, the melatonin-progesterone relationship, chrono-nutrition, and blue light.

0/6 subtopics
L5Coming soon

Epigenetics and the perimenopausal window

Why the same hormone affects each woman differently. Horvath epigenetic clock, ESR1/ESR2 methylation, and circulating miRNAs.

0/6 subtopics
L6Coming soon

Hormonal nutrigenomics

Personalization through genetics: Lua future layer. COMT and estrogens, MTHFR, CYP1A1/CYP1B1, VDR and ovarian function.

0/6 subtopics
L7Coming soon

Progesterone metabolomics and neurosteroids

The least understood and most relevant hormone in perimenopause. Biosynthesis, 5-alpha reductase, allopregnanolone and cognitive function.

0/6 subtopics
L8Coming soon

Adrenal androgens and DHEA: adrenopause

The forgotten hormone, dominant in postmenopause. DHEA and DHEA-S, peripheral aromatase, adrenopause vs menopause.

0/6 subtopics
L9Coming soon

NAD+ and ovarian function

The 2025-2026 frontier. NAD+ decline, SIRT1/SIRT3/SIRT6, NMN vs NR, and mitochondrial quality in oocytes.

0/6 subtopics
L10Coming soon

Senolytics and ovarian aging

Emerging therapies with high IP potential. Senescent cells in the ovary, dasatinib+quercetin, fisetin, and synergy with NAD+.

0/6 subtopics